Intervention Review

You have free access to this content

Vitamin E supplementation for prevention of morbidity and mortality in preterm infants

  1. Luc P Brion1,*,
  2. Edward F Bell2,
  3. Talkad S Raghuveer3

Editorial Group: Cochrane Neonatal Group

Published Online: 20 OCT 2003

Assessed as up-to-date: 30 MAR 2007

DOI: 10.1002/14651858.CD003665


How to Cite

Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD003665. DOI: 10.1002/14651858.CD003665.

Author Information

  1. 1

    University of Texas Southwestern at Dallas, Division of Neonatal-Perinatal Medicine, Dallas, Texas, USA

  2. 2

    University of Iowa, Department of Pediatrics, Iowa City, Iowa, USA

  3. 3

    University of Kansas Medical Center, Pediatrics, Kansas City, USA

*Luc P Brion, Division of Neonatal-Perinatal Medicine, University of Texas Southwestern at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas, 75390-9063, USA. Luc.Brion@UTSouthwestern.edu.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 OCT 2003

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 1 Mortality until discharge.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 2 Mortality until discharge among very low birth weight infants.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 3 Bronchopulmonary dysplasia.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 4 Bronchopulmonary dysplasia among very low birth weight infants.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 5 Bronchopulmonary dysplasia among surviving patients.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 6 Bronchopulmonary dysplasia among surviving very low birth weight infants.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 7 Radiographic signs of bronchopulmonary dysplasia persistent at 6 weeks - 2 months.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 8 Radiographic signs of bronchopulmonary dysplasia at 6 weeks - 2 months among very low birth weight infants.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 9 Patent ductus arteriosus.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 10 Patent ductus arteriosus among very low birth weight infants.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 11 Patent ductus arteriosus among surviving patients (at 10 days-10 weeks).
[Analysis 1.12]
Analysis 1.12. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 12 Patent ductus arteriosus among surviving very low birth infants (at 10 days-10 weeks).
[Analysis 1.13]
Analysis 1.13. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 13 Patent ductus arteriosus requiring treatment.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 14 Patent ductus arteriosus requiring treatment among very low birth weight infants.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 15 Sepsis after study entry.
[Analysis 1.16]
Analysis 1.16. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 16 Sepsis after study entry among very low birth weight infants.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 17 Sepsis after study entry among very low birth weight infants treated for > 1 week.
[Analysis 1.18]
Analysis 1.18. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 18 Sepsis among surviving very low birth weight infants.
[Analysis 1.19]
Analysis 1.19. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 19 Germinal matrix/intraventricular hemorrhage (grades I-IV).
[Analysis 1.20]
Analysis 1.20. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 20 Germinal matrix/intraventricular hemorrhage among very low birth weight infants.
[Analysis 1.21]
Analysis 1.21. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 21 Germinal matrix/intraventricular hemorrhage among patients with negative initial ultrasonogram.
[Analysis 1.22]
Analysis 1.22. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 22 Germinal matrix/intraventricular hemorrhage among survivors.
[Analysis 1.23]
Analysis 1.23. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 23 Germinal matrix/intraventricular hemorrhage among surviving very low birth weight infants.
[Analysis 1.24]
Analysis 1.24. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 24 Severe intraventricular hemorrhage (grade III-IV).
[Analysis 1.25]
Analysis 1.25. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 25 Severe intraventricular hemorrhage among very low birth weight infants.
[Analysis 1.26]
Analysis 1.26. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 26 Severe intraventricular hemorrhage among surviving very low birth weight infants.
[Analysis 1.27]
Analysis 1.27. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 27 Parenchymal hemorrhage (grade IV).
[Analysis 1.28]
Analysis 1.28. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 28 Parenchymal hemorrhage among very low birth weight infants.
[Analysis 1.29]
Analysis 1.29. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 29 Parenchymal hemorrhage among patients with negative initial ultrasonogram.
[Analysis 1.30]
Analysis 1.30. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 30 Parenchymal hemorrhage (Grade IV) among surviving very low birth weight infants.
[Analysis 1.31]
Analysis 1.31. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 31 Retrolental fibroplasia/retinopathy of prematurity.
[Analysis 1.32]
Analysis 1.32. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 32 Retrolental fibroplasia/retinopathy of prematurity among very low birth weight infants.
[Analysis 1.33]
Analysis 1.33. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 33 Retrolental fibroplasia/retinopathy of prematurity among infants examined/survivors.
[Analysis 1.34]
Analysis 1.34. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 34 Retrolental fibroplasia/retinopathy of prematurity among very low birth weight infants examined.
[Analysis 1.35]
Analysis 1.35. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 35 Severe retrolental fibroplasia/retinopathy of prematurity (grade 3 or worse).
[Analysis 1.36]
Analysis 1.36. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 36 Severe retrolental fibroplasia/retinopathy of prematurity (grade >= 3) among very low birth weight infants.
[Analysis 1.37]
Analysis 1.37. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 37 Severe retrolental fibroplasia/retinopathy of prematurity (grade 3 or worse) among patients examined.
[Analysis 1.38]
Analysis 1.38. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 38 Severe retrolental fibroplasia/retinopathy of prematurity among very low birth weight infants examined.
[Analysis 1.39]
Analysis 1.39. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 39 Retinal detachment among surviving infants.
[Analysis 1.40]
Analysis 1.40. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 40 Retinal detachment among surviving very low birth weight infants.
[Analysis 1.41]
Analysis 1.41. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 41 Cicatricial retrolental fibroplasia, any stage, among patients examined after discharge.
[Analysis 1.42]
Analysis 1.42. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 42 Cicatricial retrolental fibroplasia, any stage, among very low birth weight infants examined after discharge.
[Analysis 1.43]
Analysis 1.43. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 43 Blindness from retrolental fibroplasia among very low birth weight infants examined.
[Analysis 1.44]
Analysis 1.44. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 44 Necrotizing enterocolitis.
[Analysis 1.45]
Analysis 1.45. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 45 Necrotizing enterocolitis among very low birth weight infants.
[Analysis 1.46]
Analysis 1.46. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 46 Necrotizing enterocolitis among very low birth weight infants treated for > 1 week.
[Analysis 1.47]
Analysis 1.47. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 47 Necrotizing enterocolitis among survivors.
[Analysis 1.48]
Analysis 1.48. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 48 Necrotizing enterocolitis among surviving very low birth weight infants.
[Analysis 1.49]
Analysis 1.49. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 49 Serum bilirubin concentration (mg/100 ml) on day 3-5.
[Analysis 1.50]
Analysis 1.50. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 50 Serum bilirubin concentration in very low birth weight infants.
[Analysis 1.51]
Analysis 1.51. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 51 Serum bilirubin concentration on day 3-5 in a specific group (no hemolysis, polycythemia, prior transfus.
[Analysis 1.52]
Analysis 1.52. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 52 Hemoglobin concentration (g/100 ml).
[Analysis 1.53]
Analysis 1.53. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 53 Hemoglobin concentration in very low birth weight infants.
[Analysis 1.54]
Analysis 1.54. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 54 Reticulocyte count (%).
[Analysis 1.55]
Analysis 1.55. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 55 Reticulocyte count (%) in very low birth weight infants.
[Analysis 1.56]
Analysis 1.56. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 56 Reticulocyte count (million per liter).
[Analysis 1.57]
Analysis 1.57. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 57 Reticulocyte count (million per liter) in very low birth weight infants.
[Analysis 1.58]
Analysis 1.58. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 58 Number of transfusions.
[Analysis 1.59]
Analysis 1.59. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 59 Number of transfusions among survivors.
[Analysis 1.60]
Analysis 1.60. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 60 Amount of blood transfused (ml/kg) among very low birth weight infants.
[Analysis 1.61]
Analysis 1.61. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 61 Amount of blood transfused (ml/kg) among surviving low birth weight infants.
[Analysis 1.62]
Analysis 1.62. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 62 Platelet count (thousands/microliter).
[Analysis 1.63]
Analysis 1.63. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 63 Prothrombin time (PT, seconds).
[Analysis 1.64]
Analysis 1.64. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 64 Partial thromboplastin time (PTT, seconds).
[Analysis 1.65]
Analysis 1.65. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 65 Fibrinogen concentration (mg/100 ml).
[Analysis 1.66]
Analysis 1.66. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 66 Retinal hemorrhage among very low birth weight infants examined/surviving.
[Analysis 1.67]
Analysis 1.67. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 67 Reaction at site of injection.
[Analysis 1.68]
Analysis 1.68. Comparison 1 Vitamin E versus placebo or no vitamin E, Outcome 68 Reaction at site of injection in very low birth weight infants.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 1 Mortality.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 2 Bronchopulmonary dysplasia.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 3 Patent ductus arteriosus.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 4 Sepsis.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 5 Germinal matrix-intraventricular hemorrhage.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 6 Stage IV (intraparenchymal) intraventricular hemorrhage.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 7 Necrotizing enterocolitis.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Vitamin E (aqueous colloidal) versus another form of vitamin E (olive oil), Outcome 8 Exchange transfusion.